These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2723133)

  • 21. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors.
    Raghavendra V; Naidu PS; Kulkarni SK
    Brain Res; 2001 Jun; 904(1):149-52. PubMed ID: 11516422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melatonin potentiates the effects of naloxone on reserpine-induced catalepsy in the rat.
    Sandyk R; Fisher H
    Int J Neurosci; 1989 Sep; 48(1-2):125-7. PubMed ID: 2583927
    [No Abstract]   [Full Text] [Related]  

  • 23. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat.
    Kozell L; Sandyk R; Wagner GC; Fisher H
    Life Sci; 1987 Oct; 41(14):1739-44. PubMed ID: 3657380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melatonin for the treatment of tardive dyskinesia.
    Nelson LA; McGuire JM; Hausafus SN
    Ann Pharmacother; 2003; 37(7-8):1128-31. PubMed ID: 12841828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin precursor effects in tardive dyskinesia.
    Nasrallah HA; Smith RE; Dunner FJ; McCalley-Whitters M
    Psychopharmacology (Berl); 1982; 77(3):234-5. PubMed ID: 6812144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2002; 112(4):851-9. PubMed ID: 12088744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case report of adverse effect of reserpine on tardive dyskinesia.
    Donatelli A; Geisen L; Feuer E
    Am J Psychiatry; 1983 Feb; 140(2):239-40. PubMed ID: 6129810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
    Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naloxone-induced seizures in rats infected with Borna disease virus.
    Solbrig MV; Koob GF; Lipkin WI
    Neurology; 1996 Apr; 46(4):1170-1. PubMed ID: 8780117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease.
    Sandyk R; Snider SR
    Am J Psychiatry; 1986 Jan; 143(1):118. PubMed ID: 3002197
    [No Abstract]   [Full Text] [Related]  

  • 31. Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride.
    Koch HJ; Szecsey A; Vogel M; Fischer-Barnicol D
    Int J Clin Pract; 2003 Mar; 57(2):147-9. PubMed ID: 12661802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative mechanisms and tardive dyskinesia.
    Lohr JB; Kuczenski R; Niculescu AB
    CNS Drugs; 2003; 17(1):47-62. PubMed ID: 12467492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dexamethasone suppression test nonsuppression and tardive dyskinesia.
    Sandyk R
    Acta Psychiatr Scand; 1989 Jul; 80(1):108-9. PubMed ID: 2763856
    [No Abstract]   [Full Text] [Related]  

  • 34. Choline chloride in animal models of tardive dyskinesia.
    Davis KL; Hollister LE; Vento AL; Simonton S
    Life Sci; 1978 May; 22(19):1699-707. PubMed ID: 566830
    [No Abstract]   [Full Text] [Related]  

  • 35. Tardive dyskinesia associated with depression in a bipolar patient: possible role of melatonin.
    Sandyk R
    Int J Neurosci; 1990 May; 52(1-2):79-83. PubMed ID: 1979969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonazepam and phenobarbital in tardive dyskinesia.
    Bobruff A; Gardos G; Tarsy D; Rapkin RM; Cole JO; Moore P
    Am J Psychiatry; 1981 Feb; 138(2):189-93. PubMed ID: 6109454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
    Kapitsa IG; Ivanova EA; Kokshenev II; Nepoklonov AV; Val'dman EA; Voronina TA
    Eksp Klin Farmakol; 2014; 77(5):3-5. PubMed ID: 25033563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
    Maranis S; Stamatis D; Tsironis C; Konitsiotis S
    Eur J Pharmacol; 2012 May; 683(1-3):71-7. PubMed ID: 22410193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tardive dyskinesia: etiology, clinical features and therapy].
    Furer V; Lichtenberg P; Heresco-Levy U
    Harefuah; 2001 Mar; 140(3):248-52. PubMed ID: 11303354
    [No Abstract]   [Full Text] [Related]  

  • 40. Lack of efficacy of pindolol in tardive dyskinesia.
    Greendyke RM; Webster JC; Kim J; Kim H
    Am J Psychiatry; 1988 Oct; 145(10):1318-9. PubMed ID: 3048123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.